Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention of Recurrent VTE in Patients with Active Cancer By Ogkologos - April 29, 2025 713 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the API-CAT study Source RELATED ARTICLESMORE FROM AUTHOR Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Tarlatamab Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer MOST POPULAR FDA Approves Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma April 27, 2022 With Two FDA Approvals, Prostate Cancer Treatment Enters the PARP Era June 11, 2020 Pralsetinib: Measures to Minimise Increased Risk for Tuberculosis May 25, 2023 Trial Suggests Expanded Role for Blinatumomab in Treating ALL January 25, 2023 Load more HOT NEWS FDA Approves Nivolumab in Combination with Cisplatin and Gemcitabine for Unresectable... Grandma Who Sent Accidental Text To Stranger Spends 6th Thanksgiving With... Combining Radiotherapy with SOC Plus Abiraterone Improves rPFS in Patients with... What the Budget 2021 means for research
